Estrogen-progestin replacement therapy and breast cancer risk: The Women's Health Study (United States)

Cancer Causes and Control

Volumn 13, Issue 9, 2002, Pages 847-854

  Porch, Juliet V ^a   Lee, I Min ^a,b   Cook, Nancy R ^a   Rexrode, Kathryn M ^a   Buring, Julie E ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Estrogen; Menopause; Progesterone; Women

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; UNITED STATES;

EID: 0036842899     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020617415381     Document Type: Article

References (26)

1. Colditz G (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90: 814-823.
2. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies on 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047-1059.
3. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293-297.
4. Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort. Int J Cancer 67: 37.
5. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10: 253-260.
6. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast cancer risk following long-term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 81: 339-344.
7. Schairer C (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-491.
8. Ross RK (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328-340.
9. Ewertz M (1988) Influence of noncontraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42: 832-838.
10. Kaufman DW, Palmer J, de Mouzon J, et al. (1991) Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study. Am J Epidemiol 134: 1375-1385.
11. Palmer JR, Rosenberg L, Clarke EA, Miller D, Shapiro S (1991) Breast cancer risk after estrogen replacement therapy: Results from the Toronto Breast Cancer Study. Am J Epidemiol 134: 1386-1401.
12. Newcomb PA, Longnecker MP, Storer BE, et al. (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142: 788-795.
13. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274: 137-142.
14. Buring JE, Hennekens CH (1992) The Women's Health Study: Rationale and background. J Myocardial Ischemia 4: 30-40.
15. Buring JE, Hennekens CH (1992) The Women's Health Study: Summary of the study design. J Myocardial Ischemia 4: 27-29.
16. Rexrode KM, Lee I-M, Cook NR, Hennekens CH, Buring JE (2000) Baseline characteristics of participants in the Women's Health Study. J Womens Health 9: 19-27.
17. LaCroix AZ, Burke W (1997) Breast cancer and hormone replacement therapy. Lancet 350: 1042-1044.
18. Cox DR (1972) Regression models and life tables. J R Stat Soc 34: 187-220.
19. Colditz G, Rosner B (1998) Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 147S: 645.
20. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
21. Stanford JL, Thomas DB (1993) Exogenous progestins and breast cancer. Epidemiol Rev 15: 98-107.
22. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 174: 93-100.
23. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17-35.
24. Hofseth LJ, Raafat AM, Osuch JR, Rathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559-4565.
25. Greendale GA, Reboussin BA, Sie A, et al. (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density: Postmenopausal estrogen/progestin interventions (PEPI) investigators. Ann Intern Med 130: 262-269.
26. Kuller LH (2000) Re: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 1100-1101.